

Fadi Fakhouri

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/186839/fadi-fakhouri-publications-by-year.pdf>

Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

61
papers

4,542
citations

29
h-index

64
g-index

64
ext. papers

5,609
ext. citations

8.3
avg, IF

5.28
L-index

#	Paper	IF	Citations
61	Prevalence and Factors Associated with Opioid Prescription in Swiss Chronic Hemodialysis Patients. <i>Kidney and Dialysis</i> , 2022 , 2, 6-15		
60	What is the impact of blood pressure on neurological symptoms and the risk of ESKD in primary and secondary thrombotic microangiopathies based on clinical presentation: a retrospective study.. <i>BMC Nephrology</i> , 2022 , 23, 39	2.7	0
59	Pregnancy-triggered atypical hemolytic uremic syndrome (aHUS): a Global aHUS Registry analysis. <i>Journal of Nephrology</i> , 2021 , 34, 1581-1590	4.8	7
58	Eosinophilia Due to Central Venous Catheter in Hemodialysis Patients. <i>Kidney International Reports</i> , 2021 , 6, 1189-1191	4.1	0
57	Thrombotic microangiopathy in aHUS and beyond: clinical clues from complement genetics. <i>Nature Reviews Nephrology</i> , 2021 , 17, 543-553	14.9	14
56	High levels of interleukine-6 in ascites prevent ascites reinfusion during hemodialysis. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021 , 45, 101734	2.4	
55	ANCA-Negative Pauci-Immune Necrotizing Glomerulonephritis: A Case Series and a New Clinical Classification. <i>American Journal of Kidney Diseases</i> , 2021 ,	7.4	1
54	Ecuzumab discontinuation in children and adults with atypical hemolytic-uremic syndrome: a prospective multicenter study. <i>Blood</i> , 2021 , 137, 2438-2449	2.2	21
53	Atypical HUS relapse triggered by COVID-19. <i>Kidney International</i> , 2021 , 99, 267-268	9.9	22
52	Spectrum of Kidney Involvement in Patients with Myelodysplastic Syndromes. <i>Kidney International Reports</i> , 2021 , 6, 746-754	4.1	3
51	Letter regarding "Minimal change disease relapse following SARS-CoV-2 mRNA vaccine". <i>Kidney International</i> , 2021 , 100, 458-459	9.9	9
50	Infection in Patients with Suspected Thrombotic Microangiopathy Based on Clinical Presentation. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021 , 16, 1355-1364	6.9	0
49	COVID-19 as a potential trigger of complement-mediated atypical HUS. <i>Blood</i> , 2021 , 138, 1777-1782	2.2	8
48	Malignant hypertension and thrombotic microangiopathy: complement as a usual suspect. <i>Nephrology Dialysis Transplantation</i> , 2020 ,	4.3	2
47	Antenatal corticosteroid therapy and COVID-19: Pathophysiological considerations. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2020 , 99, 952	3.8	8
46	Practical management of C3 glomerulopathy and Ig-mediated MPGN: facts and uncertainties. <i>Kidney International</i> , 2020 , 98, 1135-1148	9.9	8
45	The authors reply. <i>Kidney International</i> , 2020 , 98, 232	9.9	3

44	C3 glomerulonephritis in a patient treated with anti-PD-1 antibody. <i>European Journal of Cancer</i> , 2020 , 125, 46-48	7.5	3
43	Management of thrombotic microangiopathy in pregnancy and postpartum: report from an international working group. <i>Blood</i> , 2020 , 136, 2103-2117	2.2	23
42	Collapsing glomerulopathy in a COVID-19 patient. <i>Kidney International</i> , 2020 , 98, 228-231	9.9	175
41	Atypical and secondary hemolytic uremic syndromes have a distinct presentation and common genetic risk factors. <i>Kidney International</i> , 2019 , 95, 1443-1452	9.9	40
40	Etiology and Outcomes of Thrombotic Microangiopathies. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2019 , 14, 557-566	6.9	41
39	Impact of hypertensive emergency and rare complement variants on the presentation and outcome of atypical hemolytic uremic syndrome. <i>Haematologica</i> , 2019 , 104, 2501-2511	6.6	18
38	The authors reply. <i>Kidney International</i> , 2019 , 96, 517-518	9.9	
37	Use of Highly Individualized Complement Blockade Has Revolutionized Clinical Outcomes after Kidney Transplantation and Renal Epidemiology of Atypical Hemolytic Uremic Syndrome. <i>Journal of the American Society of Nephrology: JASN</i> , 2019 , 30, 2449-2463	12.7	42
36	Shiga toxin-producing Escherichia coli-associated hemolytic uremic syndrome in solid organ transplant recipients. <i>Kidney International</i> , 2019 , 96, 1423-1424	9.9	2
35	Eculizumab Use for Kidney Transplantation in Patients With a Diagnosis of Atypical Hemolytic Uremic Syndrome. <i>Kidney International Reports</i> , 2019 , 4, 434-446	4.1	33
34	Dampening of CD8+ T Cell Response by B Cell Depletion Therapy in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. <i>Arthritis and Rheumatology</i> , 2019 , 71, 641-650	9.5	14
33	Patterns of Clinical Response to Eculizumab in Patients With C3 Glomerulopathy. <i>American Journal of Kidney Diseases</i> , 2018 , 72, 84-92	7.4	55
32	Clinical and genetic predictors of atypical hemolytic uremic syndrome phenotype and outcome. <i>Kidney International</i> , 2018 , 94, 408-418	9.9	61
31	Bronchiectasis is highly prevalent in anti-MPO ANCA-associated vasculitis and is associated with a distinct disease presentation. <i>Seminars in Arthritis and Rheumatism</i> , 2018 , 48, 70-76	5.3	19
30	Haemolytic uraemic syndrome. <i>Lancet, The</i> , 2017 , 390, 681-696	4.0	246
29	International and multidisciplinary expert recommendations for the use of biologics in systemic lupus erythematosus. <i>Autoimmunity Reviews</i> , 2017 , 16, 650-657	13.6	19
28	Hemolytic Uremic Syndrome in Pregnancy and Postpartum. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2017 , 12, 1237-1247	6.9	104
27	C5 nephritic factors drive the biological phenotype of C3 glomerulopathies. <i>Kidney International</i> , 2017 , 92, 1232-1241	9.9	52

26	Pathogenic Variants in Complement Genes and Risk of Atypical Hemolytic Uremic Syndrome Relapse after Eculizumab Discontinuation. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2017 , 12, 50-59	6.9	106
25	Antagonist Anti-CD28 Therapeutics for the Treatment of Autoimmune Disorders. <i>Antibodies</i> , 2017 , 6,	7	4
24	Translational implications of endothelial cell dysfunction in association with chronic allograft rejection. <i>Pediatric Nephrology</i> , 2016 , 31, 41-51	3.2	9
23	Terminal Complement Inhibitor Eculizumab in Adult Patients With Atypical Hemolytic Uremic Syndrome: A Single-Arm, Open-Label Trial. <i>American Journal of Kidney Diseases</i> , 2016 , 68, 84-93	7.4	162
22	Loss of DGK α induces endothelial cell activation and death independently of complement activation. <i>Blood</i> , 2015 , 125, 1038-46	2.2	63
21	Eculizumab for treatment of rapidly progressive C3 glomerulopathy. <i>American Journal of Kidney Diseases</i> , 2015 , 65, 484-9	7.4	74
20	Heparin use during dialysis sessions induces an increase in the antiangiogenic factor soluble Flt1. <i>Nephrology Dialysis Transplantation</i> , 2014 , 29, 1225-31	4.3	13
19	Insights from the use in clinical practice of eculizumab in adult patients with atypical hemolytic uremic syndrome affecting the native kidneys: an analysis of 19 cases. <i>American Journal of Kidney Diseases</i> , 2014 , 63, 40-8	7.4	65
18	Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome. <i>Nature Genetics</i> , 2013 , 45, 531-6	6.3	357
17	Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2013 , 8, 554-62	6.9	426
16	C3 glomerulopathy: consensus report. <i>Kidney International</i> , 2013 , 84, 1079-89	9.9	398
15	Thrombotic microangiopathy: eculizumab for atypical haemolytic uraemic syndrome: what next?. <i>Nature Reviews Nephrology</i> , 2013 , 9, 495-6	14.9	10
14	Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations. <i>Journal of the American Society of Nephrology: JASN</i> , 2010 , 21, 859-67	12.7	320
13	Treatment with human complement factor H rapidly reverses renal complement deposition in factor H-deficient mice. <i>Kidney International</i> , 2010 , 78, 279-86	9.9	67
12	C3 glomerulopathy: a new classification. <i>Nature Reviews Nephrology</i> , 2010 , 6, 494-9	14.9	265
11	Urinary tract obstruction due to extramedullary plasmacytoma: report of two cases. <i>CKJ: Clinical Kidney Journal</i> , 2009 , 2, 143-6	4.5	1
10	Factor H, membrane cofactor protein, and factor I mutations in patients with hemolysis, elevated liver enzymes, and low platelet count syndrome. <i>Blood</i> , 2008 , 112, 4542-5	2.2	98
9	Primary glomerulonephritis with isolated C3 deposits: a new entity which shares common genetic risk factors with haemolytic uraemic syndrome. <i>Journal of Medical Genetics</i> , 2007 , 44, 193-9	5.8	223

8	Does hemolytic uremic syndrome differ from thrombotic thrombocytopenic purpura?. <i>Nature Clinical Practice Nephrology</i> , 2007 , 3, 679-87		45
7	ANCA-negative pauci-immune renal vasculitis: histology and outcome. <i>Nephrology Dialysis Transplantation</i> , 2005 , 20, 1392-9	4.3	121
6	The man with "milk-shake" urine. <i>Lancet, The</i> , 2004 , 364, 1638	4.0	2
5	Steroid-sensitive nephrotic syndrome: from childhood to adulthood. <i>American Journal of Kidney Diseases</i> , 2003 , 41, 550-7	7.4	120
4	The expanding spectrum of renal diseases associated with antiphospholipid syndrome. <i>American Journal of Kidney Diseases</i> , 2003 , 41, 1205-11	7.4	76
3	Crystals from fat. Acute oxalate nephropathy. <i>Nephrology Dialysis Transplantation</i> , 2002 , 17, 1348-50	4.3	11
2	Mesangial IgG glomerulonephritis: a distinct type of primary glomerulonephritis. <i>Journal of the American Society of Nephrology: JASN</i> , 2002 , 13, 379-387	12.7	13
1	Liver involvement in autosomal-dominant polycystic kidney disease: therapeutic dilemma. <i>Journal of the American Society of Nephrology: JASN</i> , 2000 , 11, 1767-1775	12.7	103